{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:36Z","timestamp":1793978856549,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002102","name":"King's Health Partners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W028018\/1"],"award-info":[{"award-number":["MR\/W028018\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neubiorev.2026.106806","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:33:25Z","timestamp":1780727605000},"page":"106806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An umbrella review of inflammatory biomarkers and their relationship to treatment response in MDD"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5265-0457","authenticated-orcid":false,"given":"Luke","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Utulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Utulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Utulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Strawbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"July","key":"10.1016\/j.neubiorev.2026.106806_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis\u2019","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neubiorev.2026.106806_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jad.2022.09.011","article-title":"Understanding treatment-resistant depression using \u201comics\u201d techniques: a systematic review","author":"Amasi-Hartoonian","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106806_bib3","first-page":"132","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"\u2019. JBI Evid. Implement."},{"key":"10.1016\/j.neubiorev.2026.106806_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00458","article-title":"Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium","author":"Arteaga-Henriquez","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106806_bib5","doi-asserted-by":"crossref","unstructured":"Barnes, Mondelli, and Pariante. 2017. \u2018Genetic Contributions of Inflammation to Depression\u2019. Neuropsychopharmacology (Basingstoke, Hampshire, United Kingdom)) 42 (1).","DOI":"10.1038\/npp.2016.169"},{"key":"10.1016\/j.neubiorev.2026.106806_bib6","doi-asserted-by":"crossref","unstructured":"Basterzi, Yazici, Buturak, and Cimen. 2010. \u2018Effects of Venlafaxine and Fluoxetine on Lymphocyte Subsets in Patients with Major Depressive Disorder: A Flow Cytometric Analysis\u2019. Progress in Neuro-Psychopharmacology and Biological Psychiatry (New York, United States)) 34 (1).","DOI":"10.1016\/j.pnpbp.2009.09.025"},{"issue":"5","key":"10.1016\/j.neubiorev.2026.106806_bib7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","article-title":"GM-CSF: from growth factor to central mediator of tissue inflammation","volume":"45","author":"Becher","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000071","article-title":"Conducting umbrella reviews","volume":"1","author":"Belbasis","year":"2022","journal-title":"BMJ Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The GM\u2013CSF\/IL-3\/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00702-018-1844-x","article-title":"Blood-based biomarkers predicting response to antidepressants","volume":"126","author":"Busch","year":"2019","journal-title":"J. Neural Transm."},{"issue":"10","key":"10.1016\/j.neubiorev.2026.106806_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-024-01526-z","article-title":"The role of inflammation in depression and beyond: a primer for clinicians\u2019","volume":"26","author":"Calagua-Bedoya","year":"2024","journal-title":"Curr. Psychiatry Rep."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol. Bull."},{"issue":"December","key":"10.1016\/j.neubiorev.2026.106806_bib13","article-title":"Translational evidence for the inflammatory response system (IRS)\/compensatory immune response system (CIRS) and neuroprogression theory of major depression","volume":"111","author":"Debnath","year":"2021","journal-title":"Progress. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"March","key":"10.1016\/j.neubiorev.2026.106806_bib14","article-title":"Inflammatory markers associated with electroconvulsive therapy response in patients with depression: a meta-analysis","volume":"170","author":"Dellink","year":"2025","journal-title":"Neurosci. & Biobehav. Rev."},{"key":"10.1016\/j.neubiorev.2026.106806_bib15","author":"Depression and Other Common Mental Disorders: Global Health Estimates","year":"2017"},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106806_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.64719\/pb.4425","article-title":"Inflammatory biomarker and response to antidepressant in major depressive disorder: a systematic review and meta-analysis","volume":"52","author":"Gasparini","year":"2022","journal-title":"Psychopharmacol. Bull."},{"issue":"January","key":"10.1016\/j.neubiorev.2026.106806_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2024.09.064","article-title":"Cause-specific mortality in treatment-resistant major depression: population-based cohort study","volume":"368","author":"Gustafsson","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neubiorev.2026.106806_bib19","article-title":"SuPAR in major depression: association with 26 weeks antidepressant response and 10-year depression outcomes","volume":"33","author":"Haupt","year":"2023","journal-title":"Brain Behav. & Immun. - Health"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib20","article-title":"Machine learning for comparative antidepressant selection in major depressive disorder: systematic review","volume":"13","author":"He","year":"2026","journal-title":"JMIR Ment. Health"},{"issue":"10","key":"10.1016\/j.neubiorev.2026.106806_bib21","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1017\/S0033291712000128","article-title":"Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis","volume":"42","author":"Hiles","year":"2012","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib22","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13245","article-title":"An association between the inflammatory biomarker GlycA and depressive symptom severity","volume":"82","author":"Huckvale","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"March","key":"10.1016\/j.neubiorev.2026.106806_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mehy.2017.01.013","article-title":"The fibrinolytic system: a new target for treatment of depression with psychedelics","volume":"100","author":"Idell","year":"2017","journal-title":"Med. Hypotheses"},{"issue":"10","key":"10.1016\/j.neubiorev.2026.106806_bib24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1185\/03007995.2010.517716","article-title":"Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder","volume":"26","author":"Ivanova","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.neubiorev.2026.106806_bib25","first-page":"4195","article-title":"Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis","volume":"55","author":"K\u00f6hler","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s43556-024-00205-y","article-title":"Treatment-resistant depression: molecular mechanisms and management","volume":"5","author":"Kajumba","year":"2024","journal-title":"Mol. Biomed."},{"issue":"18","key":"10.1016\/j.neubiorev.2026.106806_bib27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1080\/14656566.2023.2281582","article-title":"Psychedelics for treatment resistant depression: are they game changers?","volume":"24","author":"Kalfas","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.neubiorev.2026.106806_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/15622975.2017.1355473","article-title":"Antidepressant efficacy of electroconvulsive therapy is associated with a reduction of the innate cellular immune activity in the cerebrospinal fluid in patients with depression","volume":"19","author":"Kranaster","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib29","article-title":"Biomarkers predicting antidepressant treatment response: how can we advance the field?","volume":"35","author":"Labermaier","year":"2013","journal-title":"Dis. Markers"},{"issue":"20","key":"10.1016\/j.neubiorev.2026.106806_bib30","doi-asserted-by":"crossref","first-page":"10092","DOI":"10.3390\/ijms262010092","article-title":"The role of interleukin-8 (IL-8) in treatment-resistant depression: a review of mechanisms, biomarker potential, and therapeutic implications","volume":"26","author":"Lisowska","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"ember","key":"10.1016\/j.neubiorev.2026.106806_bib31","article-title":"Predicting rTMS treatment response in depression: use of machine learning models to identify the roles of metabolic and clinical factors","volume":"388","author":"Liu","year":"2025","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106806_bib32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41380-019-0474-5","article-title":"Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106806_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578587","article-title":"Peripheral and central inflammation in depression: how large is the gap and can we bridge it with PET neuroimaging and neural-derived extracellular vesicles?","volume":"403","author":"Llach","year":"2025","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106806_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/ict.2023.29075.klu","article-title":"Novel and emerging markers of chronic or low-grade inflammation","volume":"29","author":"Lucius","year":"2023","journal-title":"Integr. Complement. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106806_bib35","first-page":"115","article-title":"Key factors underpinning neuroimmune-metabolic-oxidative (NIMETOX) major depression in outpatients: paraoxonase 1 activity, reverse cholesterol transport, increased atherogenicity, protein oxidation, and differently expressed cytokine networks","volume":"46","author":"Maes","year":"2025","journal-title":"Neuro Endocrinol. Lett."},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106806_bib36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2026.106806_bib37","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","article-title":"Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis","volume":"27","author":"Medeiros","year":"2022","journal-title":"Mol. Psychiatry (Engl. )"},{"issue":"5","key":"10.1016\/j.neubiorev.2026.106806_bib38","first-page":"369","article-title":"Depression heterogeneity and its biological underpinnings: toward immunometabolic depression","volume":"88","author":"Milaneschi","year":"2020","journal-title":"Biol. Psychiatry Mol. Under Depress Treat."},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106806_bib39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/1871527316666170407151514","article-title":"Elevated C-reactive protein levels in women with bipolar disorder may be explained by a history of childhood trauma, especially sexual abuse, body mass index and age","volume":"16","author":"Moraes","year":"2017","journal-title":"CNS & Neurol. Disord. Drug. Targets"},{"issue":"December","key":"10.1016\/j.neubiorev.2026.106806_bib40","article-title":"Targeting inflammation in depression: ketamine as an anti-inflammatory antidepressant in psychiatric emergency","volume":"18","author":"Nikkheslat","year":"2021","journal-title":"Brain Behav. & Immun. - Health"},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106806_bib41","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.3390\/jcm9123793","article-title":"Peripheral markers of depression","volume":"9","author":"Nobis","year":"2020","journal-title":"J. Clin. Med."},{"issue":"ember","key":"10.1016\/j.neubiorev.2026.106806_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euroneuro.2023.07.010","article-title":"Neutrophil to lymphocyte ratio and antidepressant treatment response in patients with major depressive disorder: effect of sex and hippocampal volume","volume":"76","author":"Paolini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106806_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","article-title":"Systematic review finds overlapping reviews were not mentioned in every other overview","volume":"67","author":"Pieper","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.neubiorev.2026.106806_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.euroneuro.2021.12.005","article-title":"Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: a systematic review\u2019","author":"Pisanu","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00406-022-01418-4","article-title":"Predicting treatment outcome in depression: an introduction into current concepts and challenges","volume":"273","author":"Rost","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106806_bib46","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1176\/appi.ajp.2010.09111680","article-title":"Personalized medicine for depression: can we match patients with treatments?","volume":"167","author":"Simon","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.neubiorev.2026.106806_bib47","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","article-title":"Inflammation and clinical response to treatment in depression: a meta-analysis","volume":"25","author":"Strawbridge","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"January","key":"10.1016\/j.neubiorev.2026.106806_bib48","article-title":"Peripheral inflammatory effects of different interventions for treatment-resistant depression: a systematic review","volume":"2","author":"Strawbridge","year":"2023","journal-title":"Neurosci. Appl."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106806_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106806_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1192\/bjp.2023.148","article-title":"Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials","volume":"224","author":"Vreijling","year":"2024","journal-title":"Br. J. Psychiatry"},{"issue":"22","key":"10.1016\/j.neubiorev.2026.106806_bib51","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.12998\/wjcc.v10.i22.7872","article-title":"Effect of celecoxib on improving depression: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2022","journal-title":"World J. Clin. Cases"},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106806_bib52","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/ijms21030826","article-title":"The relationship between DNA methylation and antidepressant medications: a systematic review","volume":"21","author":"Webb","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neubiorev.2026.106806_bib53","article-title":"Effect of antidepressant treatment on peripheral inflammation markers - a meta-analysis","author":"Wiedlocha","year":"2018","journal-title":"Progress. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"September","key":"10.1016\/j.neubiorev.2026.106806_bib54","article-title":"Inflamed\u201d depression: a review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression","volume":"207","author":"Yin","year":"2024","journal-title":"Pharmacol. Res."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763426002630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763426002630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:01:09Z","timestamp":1793977269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763426002630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"alternative-id":["S0149763426002630"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2026.106806","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An umbrella review of inflammatory biomarkers and their relationship to treatment response in MDD","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2026.106806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106806"}}